Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459433 | 1.00 | CYP1A2 (0.44) | CYP1A2HTTLMNAALDH1A1TAS1R3 | |
| SCHEMBL12505564 | 1.00 | CYP1A2 (0.44) | CYP1A2HTTLMNAALDH1A1TAS1R3 | |
| SCHEMBL12505565 | 1.00 | CYP1A2 (0.44) | CYP1A2HTTLMNAALDH1A1TAS1R3 | |
| SCHEMBL10247297 | 0.85 | HTT (0.40) | HTTLMNAALDH1A1KDM4EPOLB | |
| SCHEMBL354998 | 0.85 | HTT (0.40) | HTTLMNAALDH1A1KDM4EPOLB | |
| SCHEMBL28798843 | 0.80 | LMNA (0.36) | HTTLMNAALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL15945562 | 0.77 | LMNA (0.46) | HTTLMNAALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL16543123 | 0.77 | LMNA (0.46) | HTTLMNAALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL19973512 | 0.76 | TAS1R3 (0.40) | CYP1A2LMNATAS1R3TAS1R1KMT2A | |
| SCHEMBL19973513 | 0.76 | TAS1R3 (0.40) | CYP1A2LMNATAS1R3TAS1R1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2012012322-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015943-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | CYP1A2 1438/4885HTT 113/4885LMNA 1529/4885 |
| US-20140243335-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, H1-3 | CYP1A2 519/4885HTT 50/4885LMNA 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.